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Colchicine triggered severe rhabdomyolysis
after long-term low-dose simvastatin
therapy: a case report
Clara Frydrychowicz1*†, Bastian Pasieka2†, Matthias Pierer2, Wolf Mueller1, Sirak Petros2 and Lorenz Weidhase2
Abstract
Background: Rhabdomyolysis is a widely recognized yet rare complication in statin use. Rhabdomyolysis might be
triggered by the prescription of high doses of statins or by statin accumulation due to interactions with concomitant
medication. Muscle cell destruction as evidenced by myoglobin elevation can induce potentially life-threatening acute
renal failure.
Case presentation: We report a case of a 70-year-old obese white man with sudden onset of severe rhabdomyolysis
with consecutive renal failure. His medication included low-dose simvastatin, which he had taken for 6 years up until
the event. The statin was withdrawn immediately. After 3 days of veno-venous hemofiltration his renal function was
completely restored.
Conclusions: Clinicians in both primary and special care might be unaware that side effects of statins do occur even
after a long uneventful statin medication; they should be advised not to exclude that possibility upfront, even if a
patient has tolerated the medication for years.
Keywords: Case report, Rhabdomyolysis, Statin therapy, Anti-HMGCR-antibody, Statin-associated myopathies (SAM),
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Background
Statins are a common group of cholesterol-lowering
pharmaceuticals, with the shared pharmacodynamical
characteristic of 3-Hydroxy-3-Methylglutaryl-Coenzym-
A-Reduktase (3-HMG-CoA) inhibition, the key enzyme
in cholesterol synthesis. Inhibition of 3-HMG-CoA by sta-
tins is the most effective way of lowering low-density lipo-
protein (LDL) cholesterol. Even though adverse effects are
frequent, severe complications occur in less than one out
of 10,000 patients [1]. Between 2005 and 2011 the US
Food and Drug Administration (FDA) Adverse Event
Reporting System identified 147,789 case reports with sus-
pected statin-associated myopathy (SAM), including pa-
tients with rhabdomyolysis. Rhabdomyolysis as a major
statin-associated adverse effect has been reported for all
available statins [2] with the highest rate reported for
simvastatin [2]. The incidence of clinically relevant
rhabdomyolysis is not well defined, but large cohort stud-
ies showed incidences of 0.1% [3]. Rhabdomyolysis is de-
fined by creatine kinase (CK) levels at least 10 times
normal and reflects acute and massive muscle fiber necro-
sis accompanied by the release of muscle-related metabo-
lites into the bloodstream [4]. Mortality in general is low
with 0.15 deaths per 1 million [5]. Patients with rhabdo-
myolysis present with muscle weakness, myalgia and
brown “tea-colored” urine. Concomitant statin medication
in a patient with signs of rhabdomyolysis strongly suggests
SAM. Clinical diagnosis without biopsy is possible and de-
pends on multiple symptoms and signs, laboratory find-
ings, and anamnestic characteristics. Rhabdomyolysis with
histopathological confirmation has the strongest impact
on the diagnosis of SAM. For reference see Table 1. Stand-
ard therapy for rhabdomyolysis consists of urine alkaliza-
tion, aggressive intravenous administration of fluids, and
in some cases short-term dialysis and immediate with-
drawal of the statin. Here, we report a case of a sudden se-
vere rhabdomyolysis with consecutive renal failure in a
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patient who received low-dose simvastatin therapy for 6
years without previous complications. This case highlights
the difficulty of identifying potential causing or aggravat-
ing substances that can lead to SAM and provides high
quality histopathological and immunohistochemical pic-
tures of a typical toxic rhabdomyolysis in a patient with
statin-induced rhabdomyolysis.
Case presentation
A 70-year-old obese white man presented with acute
kidney failure after a 1-year history of progressive
muscle weakness and severe generalized myalgia, with
difficulty in walking and climbing stairs. His past med-
ical history was significant for chronic renal dysfunction
(Kidney Disease Outcomes Quality Initiative IV),
chronic heart failure (New York Heart Association III),
coronary heart disease with acute myocardial infarction
and coronary artery bypass, chronic atrial fibrillation,
diabetes type 2, hyperlipoproteinemia, gout, and ob-
structive sleep apnea syndrome. He had a 6-year history
of low-dose simvastatin medication with a daily dose of
40 mg. Further medication included acetylsalicylic acid,
rivaroxaban, metoprolol, ramipril, furosemide, molsido-
mine, isosorbide dinitrate, pantoprazole, and insulin.
Colchicine was prescribed as required (0.5 to 1 mg). He
had no past medical history of muscular toxicity with
statin use.
On admission he was in poor general condition. A
clinical examination revealed symmetric proximal
muscle weakness of all extremities (level of strength 3/
5). Electroneurographic and myographic diagnostics
showed chronic myopathic alterations in all of the exam-
ined muscles of his upper and lower extremities. Alter-
ations were more pronounced in proximal muscle
groups of his lower extremities. He had dyspnea induced
by light exercise, edema of lower extremities, no fever,
and no rashes.
His CK was elevated with activities >334 μkat/l
(Table 2). Antibody diagnostics provided no typical
findings for classical antibody-positive autoimmune
myositis: dermatomyositis, systemic lupus erythematosus
(SLE), scleroderma-myositis overlap syndromes, and
Sjögren’s (Sj) antibody-positive autoimmune myositis.
Based on the combination of acute kidney failure with
muscle weakness and severe generalized myalgia com-
bined with an elevated CK, a muscle biopsy was per-
formed to confirm the diagnosis of SAM and exclude
possible differential diagnoses, such as polymyositis.
Histology predominantly revealed single fiber necrosis.
Necrotic muscle fibers were present throughout the bi-
opsy in a scattered distribution. Some necrotic fibers
were in a state of macrophage-mediated degradation
(myophagocytosis). Despite widespread scattered muscle
fiber necrosis, the tissue was devoid of an interstitial or
endomysial inflammatory infiltrate. Immunohistochem-
istry highlighted a striking sarcolemmal and cytoplasmic
upregulation of major histocompatibility complex
(MHC) class I expression. Also, complement membrane
attack complex (C5b-9)-positive deposits were detected
on endothelial cells of endomysial capillaries and on the
sarcolemma and in the cytoplasm of necrotic muscle fi-
bers (Fig. 1). The histopathological diagnosis of SAM
was made, followed by serum testing for the anti-
HMGCR antibody. No anti-HMGCR antibody was
detected.
Acute renal failure, which was induced by muscle ne-
crosis, necessitated a continuous veno-venous hemofil-
tration (CVVH). Simvastatin was withdrawn and
replaced by Ezetrol (ezetimibe). After 3 days of CVVH,
his renal function was completely restored. After 15 days
his myoglobin and CK levels had normalized (Fig. 2). He
was discharged without further complaints on day 18
after hospitalization.
Discussion
In clinical practice up to 10% of patients with statin
medication develop at least mild forms of myopathy [6].
This constitutes an underestimated side effect as was
Table 1 Diagnosis of statin-induced myopathy
Feature Points
Symmetrical myalgia 1
Occurrence within 4 weeks from the start of statin therapy 1
Symptoms resolving with withdrawal of therapy 1
Family history of statin-induced myopathy 1
Elevation of creatine kinase 2
Positive re-challenge test 2
Confirmed rhabdomyolysis 5
Histological confirmation of statin-induced myopathy 5
Characteristic features allow classification of patients who have a possible
statin-induced myopathy (1–2 points), probable statin-induced myopathy (3–4
points), or definite statin-induced myopathy (>5 points) [9]
Table 2 Patient laboratory data on hospitalization
Parameter Value Reference
CK >334 μkat/l 0.63–2.91 μkat/l
Myoglobin 21896 μg/l 28–72 μg/l
ASAT 4.54 μkat/l 0.17–0.85 μkat/l
LDH 22.54 μkat/l 2.25–3.75 μkat/l
Creatinine 596 μmol/l 59–104 μmol/l
GFR MDRD 8.7 ml/min
Urea 50.7 mmol/l <11.9mmol/l
TSH 0.928 mU/l 0.4–3.77 mU/l
ASAT aspartate-aminotransferase, CK creatine kinase, GFR glomerular filtration
rate, LDH lactate dehydrogenase, MDRD Modification of Diet in Renal Disease,
TSH Thyrotropin
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underlined in the Primo Trial; an observational study of
muscular symptoms in a randomized population of 7924
patients with hyperlipidemia [6]. In 2012, Germany reg-
istered more than 3.2 billion statin prescriptions, which
leads to an expectation of a large number of affected or
symptomatic patients [7]. For patients with long-term
statin usage, a recently published meta-analysis by the
Cholesterol Treatment Trialists’ Collaboration states the
risk of myopathy to be as low as 0.5 per 1000 patients
over 5 years of statin treatment [8]. Almost 30% of
statin-associated incidences occur within the first year of
treatment [9]. However, onset of muscular side effects
has been documented between 2 months and up to 10
years after initiation of statin therapy [4]. Our case con-
firms and underscores these observations. Six years after
well tolerated and uneventful simvastatin medication,
our patient suddenly developed a severe statin-
associated rhabdomyolysis, which was histologically
compatible with the diagnosis of SAM. To date, how-
ever, the definition of SAM remains unclear; in particu-
lar, the diagnostic criteria of SAM are ill defined, which





Fig. 1 a Skeletal muscle with numerous scattered necrotic fibers (*) without signs of inflammation (hematoxylin and eosin, ×100). b Single
skeletal muscle fiber in a state of myophagocytosis (hematoxylin and eosin, ×200); * marks another fresh single fiber necrosis. c Detection of
membrane attack complex-positive immune complexes on small vessels (arrowheads), endomysial capillaries, sarcolemma, and cytoplasm in
necrotic muscle fibers (*) (membrane attack complex, ×200). d Clear sarcolemmal and cytoplasmic upregulation of major histocompatibility




























Fig. 2 Timely normalization of myoglobin and creatine kinase levels after initiating supportive therapy (continuous veno-venous hemofiltration)
and cessation of simvastatin medication. CK creatine kinase, Myo myoglobin
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and seriousness of SAM [10]. There is general consent
that statin can cause several muscle-related complaints.
These may range from mild myalgia, may lead to mani-
fest myopathy and myositis-mimicking symptoms, and
may culminate in severe rhabdomyolysis. The latter may
– when not recognized early enough – induce crush kid-
ney with consecutive renal failure and death [11].
The exact mechanism of SAM still remains elusive. Sev-
eral theories exist ranging from membrane destabilization
due to decreased cholesterol content of skeletal muscle
plasma membrane, impaired mitochondrial function due
to coenzyme Q10 depletion, disturbed calcium metabol-
ism, and vitamin D deficiency [11]. Also, there are various
co-medications that increase the risk of SAM, mostly by
interference of the metabolizing cytochrome p450 system
(CYP3A4, CYP2C). In particular, the fibric acid derivative
gemfibrozil is known to aggravate the symptoms and se-
verity of SAM [12]. The development of statin-associated
muscle problems is dose-dependent [10]. However, severe
cases of SAM have been reported in patients under low-
dose statin medication and without interfering medica-
tion. Documented long-term co-medication in the
presented case was devoid of potentially interfering drugs.
However, personal communication with our patient’s fam-
ily doctor revealed a newly introduced colchicine medica-
tion in close temporal vicinity of clinically manifest
rhabdomyolysis. Colchicine was prescribed because
muscle pain was misinterpreted as a potential gout attack.
Colchicine itself can cause myopathy. Concomitant treat-
ment of colchicine and simvastatin may exacerbate its
myotoxic effect (Table 3) [12–15]. Reported case reports
of concomitant use of statin and colchicine describe a de-
velopment of muscle weakness within 8 to 20 days after
initiation of colchicine [16–18]. Before excretion, colchi-
cine is metabolized in the liver by demethylation. Statin
metabolism may compete with colchicine for the CYP3A4
isoenzyme leading to higher serum concentrations of both
medications, thereby increasing the risk of side effects.
Advanced age, female sex, presence of comorbidities,
and alcohol consumption are further predisposing factors
for SAM [9]. Given the high number of prescriptions,
clinicians are in need of reliable risk evaluation methods
for the identification of vulnerable patients.
More recently, a self-limiting statin-induced primarily
toxic necrotizing myopathy can be distinguished from a
persisting autoimmune-mediated statin-induced necro-
tizing myopathy. The latter persists even after cessation
of statin therapy and immunosuppressive therapy [19].
In addition, anti-HMG-CoA reductase antibodies can be
detected in the serum and muscle of affected patients
[10]. Both SAM and immune-mediated necrotizing my-
opathy (IMNM) show extensive histopathological over-
lap and might not be distinguished based on biopsy
only. In the present case, IMNM was excluded by anti-
body testing (anti-HMGCR antibody, negative). Neuro-
pathologists should be aware of the possibility of
autoimmune-mediated statin-induced necrotizing myop-
athy and should recommend anti-HMG-CoA reductase
antibody testing in all patients with persistent muscle
pathology after statin arrest. Clinical monitoring of SAM
may include baseline CK levels of patients especially if
there are risk factors such as impaired renal function,
genetic myopathy in the past medical history, or signifi-
cant alcohol abuse [9, 10]. Co-medication should be
checked for potential interaction with statins, especially
if a new medication is prescribed, including herbal cures.
Patients with muscle-related symptoms and statin medi-
cation should immediately be checked for an increase in
CK. Medication should be stopped immediately and CK
levels monitored. In case of persistent elevated CK levels
after cessation of statin medication other causes of ele-
vated CK levels should be considered and investigated,
including anti-HMGCR-associated SAM [9]. Patients
should be informed about the risk of developing myop-
athy and symptoms. Despite the risk of SAM, statin
therapy remains a useful and powerful tool in cardiovas-
cular risk reduction and in reducing cardiovascular mor-
bidity and mortality. Our case emphasizes the need for
clinicians to be aware of statin-associated necrotizing
myopathy even after long-term statin treatment. The
presented patient received uneventful simvastatin ther-
apy for a period of 6 years. In addition, we identified
Table 3 Colchicine triggered simvastatin-induced myopathy: review of the literature
Case reports Age in
years
Sex Muscle symptoms Simvastatin Colchicine
Hsu et al. 2002 [17] 70 M Symmetrical proximal muscle weakness 3–4/5 – 0.5 mg daily
Baker et al. 2004 [18] 79 M Severe weakness 40 mg daily 0.6 mg daily
Justiniano et al. 2007 [16] 61 F Rhabdomyolysis 40 mg daily 0.6 mg daily
Sahin et al. 2008 [15] 30 M Proximal muscle weakness upper and lower extremities 2–3/5 20 mg daily 1.5 mg daily
Oh et al. 2012 [13] 84 M Symmetrical proximal muscle weakness 40 mg daily 1 mg (first 3 days); 0.5 mg daily
Medani and Wall 2016 [14] 60 M Muscle weakness 4/5 in all limbs except 5/5 in hip extensor – 1.5 mg daily
Current case 70 M Rhabdomyolysis 40 mg daily 0.5–1 mg as required
Case reports of concomitant simvastatin and colchicine treatment and development of muscle weakness, including rhabdomyolysis. F female, M male
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colchicine as a potential trigger of SAM in our patient
based on its metabolism potentially competing with sta-
tin metabolism. Fast recognition of SAM is mandatory
to rescue renal function and avoid life-threatening com-
plications. The treatment of choice remains immediate
cessation of statin medication and supportive care for
renal function. If recognized early enough, the outcome
is excellent.
Conclusions
We wish to alert clinicians to the fact that side effects of
statins do occur even after a long uneventful statin
medication; they should be advised not to exclude that
possibility upfront, even if a patient has tolerated the
medication for years. In particular, for patients with mul-
tiple drugs, clinicians should be aware of possible drug–
drug interactions such as colchicine and statins. In cases
in which colchicine is indicated, statins not metabolized
via the CYP3A4 system should be preferred. Patients
with muscle-related symptoms and statin medication
should immediately be checked for an increase in CK
and levels should be monitored after statin medication is
stopped. In cases of persistent elevated CK levels after
cessation of statin medication, other causes of elevated
CK levels should be considered and investigated, includ-
ing anti-HMGCR-associated SAM. Further studies are
needed to clarify the different pathogeneses of statin-
induced myopathies, as well as the optimal management
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